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A B S T R A C T
Background: The causal role of inflammatory markers on self-harm and suicidal risk has been studied using
observational data, with conflicting results. Confounding and reverse causation can lead to bias, so we appraised
question from a genetic perspective to protect against these biases. We measured associations between genetic
liability for high levels of inflammatory markers Interleukin-6 (IL-6) and C-reactive protein (CRP) on self-harm,
and conducted a secondary analysis restricted to self-harm with suicidal intent.
Methods: We conducted two sample and multivariable Mendelian randomisation (MR) to assess the effects of IL-
6 and CRP on self-harm utilising existing data and conducting new genome wide association studies to instru-
ment IL-6 and CRP, and for the outcome of self-harm.
Results: No single nucleotide polymorphisms (SNPs) reached genome-wide significance for self-harm, however
193 SNPs met suggestive significance levels (p < 5 × 10−6). We found no evidence of an association between
our instruments for IL-6 and self-harm in the two-sample MR, however we found an inverse association between
instruments for CRP and self-harm, indicating that higher levels of circulating CRP may protect against self-harm
(inverse variance weighted OR 0.92, 95%CI 0.84, 1.01, p = 0.08; MR Egger OR 0.86, 95% CI 0.74, 1.00,
p = 0.05). The direct effect estimate for IL-6 was slightly smaller in the multivariable MR than in the two sample
MR, while the CRP effect estimates were consistent with the two sample MR (OR 0.92, SE 1.05, p = 0.09).
Conclusions: Our findings are conflicting and indicate that IL-6 and CRP are not robust etiological markers of
increased self-harm or suicide risk.
1. Introduction
Self-harm and suicide are global public health priorities (World
Health Organization, 2012), however we do not currently have a suf-
ficient understanding of the aetiology of these behaviours to reliably
identify those at risk. Identifying causal influences of self-harm and
suicide risk is an important avenue of research as it may lead to novel
prevention or intervention efforts. One mechanism of interest is in-
flammation, given the emerging literature evidencing associations be-
tween altered inflammatory profiles and suicidal behavior (Serafini
et al., 2020). Suicidal behaviour is also strongly associated with de-
pression (although does not occur solely in the context of depression),
and the two may share common aetiological pathways, or depression
may partially mediate associations between inflammatory profiles and
suicidal behaviour. There are established links between inflammation
and depression, and depression and suicidal behaviour (Haapakoski
et al., 2015; Konsman, 2019), however evidence also suggests that in-
flammation may be associated with suicidal behaviour independently of
depression or other psychiatric disorders (Del Giudice and Gangestad,
2018; Huang et al., 2019). It is therefore currently unknown whether
inflammation causally impacts on risk of self-harm or suicide in the
general population. Self-harm is one of the strongest risk factors for
suicide attempt and completed suicide. Understanding the causal
antecedents of self-harm may help to identify those at risk of later
suicidal behaviour, as well as aid in development of novel treatment
and prevention approaches. Inflammation can be broadly categorised in
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two ways: systemic inflammation refers to low grade activation of the
immune system, detected through measuring levels of circulating in-
flammatory molecules, cells and cytokines (signalling molecules se-
creted by cells related to the immune response) in the bloodstream
(Konsman, 2019; Del Giudice and Gangestad, 2018). Alternately the
acute immune response to bacterial or other challenges can be measured
by changes in levels of inflammatory markers following an immune
challenge.
The precise mechanisms underlying the relationship between in-
flammation, mood and risk of self-harm or suicide are currently un-
known, and the direction of causality between inflammation and mood
is still unclear. Much more research is needed to identify the specific
biological pathways that precipitate suicidal behaviour; identifying
causal associations between inflammatory antecedents and later sui-
cidal behaviour may help to identify candidate biological pathways
(Huang et al., 2019), and advance our understanding of the nature of
the relationship between inflammatory markers and suicidal behaviour.
Various inflammatory molecules cross the blood–brain barrier, con-
veying signals to the central nervous system. Some neurons also have
receptors for inflammatory cytokines: it is plausible that inflammation
could have specific and direct effects on neuronal functioning, poten-
tially impacting on levels of neurotransmitters such as serotonin,
leading to altered mood and behaviour (Brundin et al., 2015). An al-
ternate mechanism of effect is via the kynurenine pathway, whereby
the cascade of enzymatic effects caused by inflammation ultimately
impacts on neuroinflammation, glutamate neurotransmission and the
production of serotonin. There is some evidence for altered activation
of this pathway in participants with suicidal ideation or attempt
(Brundin et al., 2015).
Studies have reported associations between higher levels of circu-
lating inflammatory markers (systemic inflammation) and self-harm,
suicide and suicide attempt (Serafini et al., 2020; Black and Miller,
2015; Brundin et al., 2017; Osimo et al., 2018; Ganança et al., 2016).
Studies examining inflammatory correlates of suicidal behaviour often
focus on clinical samples of participants with psychiatric disorders, or
post-mortem studies of individuals who have died by suicide (Osimo
et al., 2018; Courtet et al., 2015; Ekinci and Ekinci, 2017; Kim et al.,
2014; Keaton et al., 2019; Serafini et al., 2013). Findings from epide-
miological studies utilising representative non-clinical samples are in-
conclusive; some have detected associations between C-reactive protein
(CRP) and suicidal behaviour (Batty et al., 2016; Batty et al., 2018),
while others fail to identify this association independent of psychiatric
disorder (Bergmans et al., 2019; Russell et al., 2019). Findings in stu-
dies that focus on self-harm are also mixed: one study based on Danish
population registers reported no link between psoriasis (an in-
flammatory skin disease) and clinical records of self-harm (likely to be
predominantly suicidal self-harm) (Egeberg et al., 2016), however an-
other register-based study of English patients found a higher risk of self-
harm in individuals with inflammation-related conditions including
asthma, psoriasis and inflammatory polyarthropathies (Singhal et al.,
2014).
In spite of this mixed evidence, a recent systematic review of asso-
ciations between inflammatory cytokines and suicidal behaviour con-
cluded that most studies reported associations between high levels of
pro-inflammatory cytokines and suicidal behaviour, although they were
not able to assess whether there was a causal link between the two
(Serafini et al., 2020; Serafini et al., 2013). We recently explored ob-
servational associations between levels of interleukin-6 (IL-6) and CRP
in childhood and later self-harm in the Avon Longitudinal Study of
Parents and Children (ALSPAC) cohort. We detected a slightly higher
risk of self-harm in those with higher levels of IL-6, but not CRP. Our
design was prospective, however other studies reporting associations
between IL-6, CRP and suicidal behaviour are often cross-sectional and
reverse causation cannot be ruled out (Russell et al., 2019).
One causal inference method that minimises the potential influence
of confounding factors and reverse causality is Mendelian
Randomisation (MR). MR is a form of instrumental variable analysis
that utilises genetic data, capitalising on Mendel’s principles that genes
are randomly assorted in the population (Haycock et al., 2016) Using
genetic association data to investigate epidemiological associations
therefore reduces the potential of effects being due to confounding.
Using MR, we can examine whether genetic markers that confer higher
levels of IL-6 and CRP are associated with the risk of self-harm, thus
inferring whether there is likely to be a causal relationship from in-
flammation to self-harm. Similar methods have been used to study the
association between inflammation and other psychiatric outcomes such
as schizophrenia and depression (Hartwig et al., 2017; Prins et al.,
2016; Khandaker et al., 2018).
In order to conduct MR analysis on self-harm, genome-wide asso-
ciation data is required. Three genome-wide association studies
(GWASs) of suicidal behaviour have been conducted (Erlangsen et al.,
2018; Strawbridge et al., 2019; Mullins et al., 2019): two of these are
confined to suicide attempt in populations with psychiatric disorder,
and may be susceptible to collider bias due to conditioning on case
status (Paternoster and Tilling, 2017). The third examined a spectrum
of suicidal behaviour outcomes (including suicidal thoughts) in UK
Biobank using ordinal regression, assuming that these behaviours lie on
a continuum of severity (Strawbridge et al., 2019) although evidence
supporting the latter is contested (Kapur and Cooper, 2013; Mars et al.,
2014). As these existing data were not suitable for our research ques-
tions, we conducted separate GWASs of self-harm (regardless of suicidal
intent), and suicide attempt in UK Biobank as dichotomous outcomes.
In the current study we focus on chronic systemic inflammation,
indexed by two well-studied inflammatory markers: IL-6, a largely pro-
inflammatory cytokine, and CRP, an acute-phase protein released by
the liver in response to levels of inflammatory cytokines including IL-6
(Del Giudice and Gangestad, 2018). We utilised genetic epidemiological
data to investigate the potential causal role of two agents that indicate
systemic inflammation in the aetiology of self-harm and suicide at-
tempt, and estimate the magnitude of these effects.
2. Methods and materials
2.1. Study design
A two-sample MR design was used to assess whether levels of IL-6
and CRP are associated with risk of self-harm. Two sample MR utilizes
genome-wide summary data to instrument IL-6 and CRP, identifying
those with a high genetic risk for high circulating levels of these in-
flammatory markers; and investigates their association with self-harm
in a separate sample. There are three assumptions that underlie MR:
firstly that the genetic instrument is a robust predictor of the exposure;
secondly that the instrument is independent of confounders of the ex-
posure-outcome relationship; and thirdly that the instrument is only
associated with the outcome through the exposure i.e. it has no pleio-
tropic effects (Supplementary Fig. 1) (Haycock et al., 2016). As pro-
duction of IL-6 triggers CRP, this third assumption would not hold true
for IL-6 unless we include CRP within the same model: thus we con-
ducted separate two-sample MRs of IL-6 and CRP with self-harm, and
then a multivariable MR of both IL-6 and CRP with self-harm. Prior to
conducting the MR, we conducted genome-wide association studies for
IL-6 and self-harm, and meta-analysed our IL-6 GWAS with an existing
dataset (the SardiNIA cohort). Fig. 1 illustrates the data sources for our
analysis.
2.2. Measures
2.2.1. Exposure: Instruments for CRP
Instruments for CRP were derived from the summary associations
reported by the 1000 Genomes GWAS for circulating levels of CRP
(n = 48,164), described in full elsewhere (Ligthart et al., 2018). 8002
single nucleotide polymorphisms (SNPs) exceeded genome-wide
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significance thresholds. To ensure instruments were independent, strict
clumping was performed with an R2 threshold of 0.001 using the clump
command in the TwoSampleMR package in R, which uses European
samples in the 1000 genomes project reference dataset as a reference
panel for linkage disequilibrium (LD) (Hemani et al., 2018). Following
clumping, 48 SNPs remained and were utilised as instruments for CRP
(Supplementary Table 3).
2.2.2. Exposure: Instruments for IL-6
Existing genome-wide association studies of IL-6 have small sample
sizes. In order to obtain the largest sample size for our instrument, we
conducted a GWAS of IL-6 in the ALSPAC cohort (n = 3,675; see
Supplementary material) and meta-analysed our results with those of
an existing GWAS of IL-6 in 4,621 Sardinian adults (Naitza et al., 2012).
2.2.3. Meta-analysis of IL-6 GWAS
Meta-analysis of the two GWAS datasets was conducted using
METAL, assigning weights to effect size estimates by using the inverse
standard errors (Willer et al., 2010). As IL-6 is causal for CRP, and the
CRP GWAS is substantially larger than the IL-6 meta-analysis that we
performed, we hypothesised that some of the CRP hits may be IL-6
variants that we were unable to detect in our IL-6 meta-analysis. In an
attempt to enrich our IL-6 instruments, we evaluated whether any of
the CRP instruments described below were predictive of IL-6 at a p-
value adjusted for 48 multiple tests (the number of CRP instruments). In
additional, post-hoc analyses, we identified 12 SNPs previously-asso-
ciated with IL-6 from other studies (rs4556348, rs1542176, rs6743376,
rs73026617, rs11264224, rs34693607, rs2228145, rs7529229,
rs12740969, rs12083537, rs12059682, rs4845371) (Hartwig et al.,
2017; Khandaker et al., 2019; Georgakis et al., 2019:). We extracted
these SNPs from our meta-analysis, performed clumping and used the
remaining 3 SNPs in a Two Sample MR of IL-6 and self-harm.
2.2.4. Outcome: self-harm
2.2.4.1. GWAS of self-harm in UK Biobank. As detailed in the
introduction, no GWASs of self-harm as a dichotomous outcome exist,
however there have been several on a range of suicidal behaviours,
most commonly suicide attempt. Another limitation of existing studies
is that they use clinical populations, restricted to those with
psychopathology. For the genome-wide association analysis of self-
harm, we utilised data from UK Biobank, a population-based health
research resource consisting of approximately 500,000 people, aged
between 38 years and 73 years, who were recruited between the years
2006 and 2010 from across the UK (Allen et al., 2014). A full
description of the study design, participants and quality control (QC)
methods have been described in detail previously (Collins, 2012). UK
Biobank received ethical approval from the North West Multi-centre
Research Ethics Committee.
2.2.4.2. Self-harm and suicide attempt. Data on self-harm were collected
in an online mental health self-assessment questionnaire in 2016: 48%
of invited Biobank participants had completed this by October 2017.
Participants were asked “Have you ever deliberately harmed yourself,
whether or not you meant to end your life?” Data were available from
153,560 individuals with 4.37% indicating that they had ever self-
harmed. Self-harm was utilised as a dichotomous outcome (yes/no) in
the GWAS. Suicide attempt was determined from response to the
question ““Have you harmed yourself with the intention to end your
life?” 2.26% of participants indicated that they had previously self-
harmed with suicidal intent (52% of those who reported self-harm).
2.2.4.3. Genotyping and imputation, data quality control. These are
described in the supplementary methods. Quality Control filtering of
the UK Biobank data for the current study was conducted as described
in the protocol described at doi:https://doi.org//10.5523/
bris.1ovaau5sxunp2cv8rcy88688v (Mitchell et al., 2017; Bycroft
et al., 2018; Howie et al., 2011; Ruth Mitchell et al., 2019). We
restricted the sample to individuals of ‘European’ ancestry as defined by
an in-house k-means cluster analysis performed using the first four
principal components provided by UK Biobank in the statistical
software environment R.
2.2.4.4. Genome wide association analysis. GWAS was conducted using
linear mixed model (LMM) association method as implemented in
BOLT-LMM (v2.3) (Loh et al., 2015). To model population structure in
the sample we used 143,006 directly genotyped SNPs, obtained after
filtering on MAF > 0.01; genotyping rate > 0.015; Hardy-Weinberg
equilibrium p-value < 0.0001 and LD pruning to an r2 threshold of 0.1
using PLINKv2.00. Because the case fraction for suicide attempt was
low, suicide attempt GWAS data were filtered on MAF > 0.1 (Loh
et al., 2018). Genotype array and sex were adjusted for in the model.
Test statistics (betas and their corresponding standard errors) were
transformed to log odds ratios and their corresponding 95% confidence
intervals on the liability scale using a Taylor transformation expansion
series (Loh et al., 2017).
2.2.4.5. Mendelian randomisation analysis. In order to estimate the total
effect of IL-6 and CRP individually on self-harm, two sample MR was
Fig. 1. Study data sources. Notes: Dashed arrows represent data sources. Solid arrows represent analyses. Dashed-outlined boxes represent existing data sources
shared by their authors, solid outlined boxes represent new GWASs conducted for the current study. GWAS genome-wide association study. ALSPAC the Avon
Longitudinal Study of Parents and Children.
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performed for each exposure using the TwoSampleMR package in R (RC
Team, 2013). The inverse variance weighting (IVW) method was used
as the primary analysis, which calculates the inverse variance weighted
mean of ratio estimates from the instruments (i.e. the SNP IL-6 effect
estimate divided by the SNP self-harm effect estimate). An important
limitation in MR analysis is that it is difficult to prove that there is no
path from the instrument to the outcome that is not through the
exposure (also known as horizontal pleiotropy (Hemani et al., 2018).
We used ‘pleiotropy robust’ methods as sensitivity analysis in addition
to the main IVW approach. These included MR Egger regression: a
weighted linear regression of the outcome against exposure SNP
estimates (Bowden and Davey Smith, 2015), and the simple mode,
weighted mode and weighted median methods for the CRP MR as
sensitivity analyses to explore whether our findings were consistent
across different models of horizontal pleiotropy. Cochran’s Q tests were
used to assess heterogeneity of the IVW estimates, which is a global
measure of horizontal pleiotropy. Global directional pleiotropy, which
would indicate if pleiotropy was generally leading to bias, was assessed
through funnel plots and through evaluating the magnitude of the
intercept from MR Egger regression for CRP. If this formal statistical
test of directional pleiotropy is significantly different from zero, this
implies the presence of a pathway between the instruments and
outcome that is not mediated by the exposure.
To estimate the effects of IL-6 and CRP on self-harm simultaneously,
multivariable MR was conducted in R using the IVW and MR Egger
methods. This provides causal effect estimates for each biomarker,
conditioning on the other. Therefore, estimates from the two sample
MRs can be considered analogous to the total effect in an epidemiolo-
gical mediation model, and the multivariable MR estimates are the
direct effect of each biomarker on the outcome. To conduct the multi-
variable MR, all genetic instruments for IL-6 and CRP were extracted
from both the IL-6 meta-analysis and the CRP GWAS. These were har-
monised and clumped as above using the TwoSampleMR package in R.
The IVW and MR Egger effect estimates were calculated for IL-6 and
CRP on the outcome of self-harm, adjusting for the effect operating
through the other inflammatory marker. Potential global pleiotropy
was assessed through examining consistency of the causal effect esti-
mates, and F statistics were generated to assess weak instrument bias
(Hartwig et al., 2017; Khandaker et al., 2019; Georgakis et al., 2019;
Staiger and Stock, 1994).
3. Results
3.1. Self-harm and suicide attempt GWAS’s in UK Biobank
There were no SNPs that were statistically significantly associated
with self-harm in our GWAS (at p < 5 × 10−8), however 193 SNPs
met suggestive significance levels at p < 5 × 10−6 with the majority
being on chromosome 1 and 19 (Fig. 2). The ‘suggestive’ significance
threshold represents one false positive result being expected per GWAS,
as proposed by Lander and Kruglyak (Lander, 1995) Similarly, there
were no SNPs that met genome-wide significance thresholds in the
suicide attempt GWAS, 15 met suggestive thresholds (Supplementary
Fig. 2; Supplementary Table 2).
3.2. IL-6 GWAS and meta-analysis
In the GWAS of IL-6 in ALSPAC 190 single nucleotide polymorph-
isms (SNPs) on chromosomes 1 and 9 reached genome-wide sig-
nificance (p < 5 × 10−8). The meta-analysis of the SardiNIA and
ALSPAC IL-6 data resulted in 198 genome-wide significant hits from a
total sample of 8296 individuals (Fig. 3). Following clumping as de-
scribed above, this resulted in two genome-wide significant hits
(rs56383622 on chromosome 1, and rs643434 on chromosome 9) that
we utilised as instruments for IL-6 in the MR. Two further SNPs
(rs2228145 on chromosome 1 and rs505922 on chromosome 9) from
the CRP instruments were associated with IL-6 levels, however these
were in LD with our existing instruments and were subsequently ex-
cluded during clumping (Supplementary Table 4).
3.3. Estimates of the total effects of IL-6 and CRP on self-harm- two sample
MR
Effect estimates from the two sample MR of IL-6 and self-harm were
null, indicating no evidence of an association between our IL-6 instru-
ments and self-harm (Table 1). In the follow-up post-hoc analysis we
assessed the 12 SNPs previously associated with IL-6 in Hartwig et al.
(2017), Khandaker et al. (2019), Georgakis et al. (2019): Following
clumping, 3 SNPs remained (see Supplementary Table 5; rs1542176,
rs6743376, rs7529229) however only rs7529229 was significantly as-
sociated with IL-6 in our meta-analysis (p = 4.15 × 10−22) with
p > 0.2 for the other 2 SNPs. We entered these 3 SNPs as instruments
into a further 2-sample MR of IL-6 against self-harm. The IVW results
showed no association between these instruments and self-harm (OR
1.00, 95% CI 0.84, 1.19), and results were consistently null for the
instruments when assessed individually.
We found an inverse association between CRP and self-harm, in-
dicating that higher levels of circulating CRP are protective against self-
harm (IVW OR 0.92, 95%CI 0.84, 1.01, p = 0.08; MR Egger OR 0.86,
95% CI 0.74, 1.00, p = 0.05). Cochran’s Q test indicated no apparent
heterogeneity in the inverse variance estimates from each genetic var-
iant individually (IL-6 Q(1) = 0.21, p = 0.65; CRP Q(46) = 1.08,
p = 0.52) (Bowden and Davey Smith, 2015), and tests for pleiotropy in
the CRP instruments showed that the Egger intercept was not sig-
nificantly different from zero, indicating that directional pleiotropy is
unlikely (CRP intercept 0.01 SE 0.01p = 0.24). For CRP, we also cal-
culated estimates based on the weighted median and weighted mode:
methods that are more robust to pleiotropy. These methods were not
suitable for IL-6 as we had only two instruments. For CRP, the effect
estimates and confidence intervals were consistent with the IVW and
MR Egger findings, indicating that higher CRP levels may be protective
against self-harm.
3.4. Estimates of the direct effects of IL-6 and CRP on self-harm:
Multivariable MR
We found no evidence of an association between IL-6 and self-harm
in the multivariable MR (Table 2). The direct effect estimate for IL-6
was slightly smaller in the IVW multivariable MR than in the 2-sample
MR (OR reduced from 1.14 to 1.09), and the CRP effect estimates were
consistent with the 2-sample MR, supporting the finding of a reduced
risk of self-harm with increasing levels of CRP, although in the MVMR
this was no longer statistically significant (OR 0.92, SE 1.05, p = 0.09).
The MR Egger intercept of the MVMR was not large and not sig-
nificantly different from zero (intercept = −0.002, SE = 0.005,
p = 0.74), and the causal effect estimates were again largely consistent
suggesting that additional pleiotropy is not meaningfully biasing the
results. The F statistics were much lower than the rule-of-thumb cut-off
of 10 (IVW F = 2.33, p = 0.11, Egger F = 2.12, p = 0.13) indicating
weak instrument bias (Sanderson et al., 2018).
3.5. Secondary analysis: Suicide attempt outcome
We conducted a secondary analysis to explore whether our findings
were consistent with a more specific definition of self-harm with sui-
cidal intent (Tables 3 and 4). In the two-sample MR of IL-6 on suicide
attempt, lower IL-6 was associated with an increased risk of suicide
attempt, although the confidence intervals overlapped the null value
substantially as in the self-harm MR. In the two-sample MR of CRP on
suicide attempt, higher CRP was associated with an increased risk of
suicide attempt, however the confidence intervals were much wider and
overlapped with the null value and the confidence intervals in the self-
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harm analysis. Findings were consistent across different MR methods.
In the multivariable MR, the effect estimates for both IL-6 and CRP were
null (Tables 3 and 4).
4. Discussion
In our two-sample MR analyses we found no evidence of an asso-
ciation between IL-6 and self-harm, and some evidence that higher le-
vels of CRP may be protective against self-harm. Our findings suggest
conflicting evidence of a causal role of these two inflammatory agents
in the aetiology of self-harm, suggesting that different inflammatory
markers may have differential or no associations with self-harm in
European populations.
A major limitation of existing observational studies in this field is
the use of clinical samples, i.e. individuals with diagnosed psychiatric
illnesses. Although self-harm and suicide is more common in those with
psychiatric disorders (Singhal et al., 2014), the majority of those who
self-harm will not have a psychiatric diagnosis or attempt suicide (Mars
et al., 2014). Associations between inflammation and self-harm, suicide
attempt or suicide in psychiatric populations may be either confounded
by or unique to the disorder being studied. Similarly, existing GWASs of
self-harm and suicide-related behaviours are also confined to samples
that have high proportions of individuals with diagnosed psychiatric
disorders (Erlangsen et al., 2018; Mullins et al., 2019), with the ex-
ception of the current study and the recently published study using the
same UK Biobank sample (Strawbridge et al., 2019). Our finding of no
genome-wide significant associations for self-harm and suicide attempt
may indicate that these behaviours do not have a strong underlying
genetic basis, which would limit our ability to detect associations with
IL-6 and CRP in our outcome genetic dataset relating to self-harm risk,
or may be due to a cohort effect.
Both IL-6 and CRP are commonly used as biomarkers of in-
flammation. However, the mechanisms and actions of these molecules
are complex. IL-6 is a family of ten cytokines that operate via two
pathways and has pro- and anti-inflammatory effects: the classic sig-
nalling pathway which increases CRP production, and the trans-sig-
nalling pathway which is upregulated during inflammation (Konsman,
2019; Del Giudice and Gangestad, 2018; Murakami et al., 2019).
Fig. 2. A) Manhattan plot and B) quantile–quantile plot of self-harm genome wide association study results in UK Biobank.
Fig. 3. A) Manhattan plot and B) quantile–quantile plot of Interleukin-6 Meta-analysis of ALSPAC and SardiNIA cohorts.
Table 1
Two sample MR results.
Interleukin-6 (n SNPs = 2) C-reactive protein (n SNPs = 47)
Model OR 95% CI p OR 95% CI p
IVW 1.14 0.90, 1.45 0.28 0.92 0.84, 1.01 0.08
MR Egger 0.86 0.74, 1.00 0.05
Weighted median 0.88 0.78, 1.00 0.05
Simple mode 0.96 0.77, 1.21 0.76
Weighted mode 0.88 0.79, 0.98 0.02
Notes: SNP single nucleotide polymorphism (genetic instruments) IVW inverse
variance weighted, OR odds ratio CI confidence interval.
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Therefore although IL-6 acts in a pro-inflammatory manner, it also
contributes to reduction of the immune response, tissue repair and re-
generation and thus has anti-inflammatory effects (Konsman, 2019; Del
Giudice and Gangestad, 2018; Murakami et al., 2019). CRP also has
varied effects, including binding to damaged cells during the in-
flammatory response, activating neutrophils and monocytes and pro-
moting the secretion of inflammatory cytokines. It also has anti-in-
flammatory effects. The form of CRP released by the liver, and
detectable as circulating CRP, has mainly anti-inflammatory effects, but
when this encounters other signals of inflammation or cell damage it
breaks down into five identical molecules that are pro-inflammatory in
nature (Del Giudice and Gangestad, 2018; Black and Kushner, 2004).
Therefore, although elevated IL-6 and CRP may be due to inflammation,
they can exist in the absence of an inflammatory state and do not define
an inflammatory state (Konsman, 2019; Del Giudice and Gangestad,
2018), using these as markers of systemic inflammation may even be
misleading or inaccurate. Further studies are needed to examine the
role of other inflammatory molecules in relation to self-harm to explore
whether findings are consistent where molecules have solely pro- or
anti-inflammatory effects.
Our findings that higher levels of CRP are associated with reduced
risks of self-harm may not necessarily mean that inflammation is pro-
tective against self-harm: conversely the anti-inflammatory effect of
higher levels of CRP may be acting as a protective mechanism. Other
MR studies of CRP have also failed to find robust evidence for higher
disease risk with higher circulating CRP levels across a range of physical
and mental health outcomes, contrary to other observational findings
(Prins et al., 2016). Two studies have however found evidence that
higher CRP is protective against schizophrenia, mirroring our finding
regarding self-harm (Hartwig et al., 2017; Prins et al., 2016): these
authors have hypothesised that this may reflect increased susceptibility
to early-life infection, although it may also be influenced by socio-
economic or lifestyle characteristics (Hartwig et al., 2017). Equally, we
also concede the possibility that the detected association may have
arisen by chance, and our findings need replicating before further
conclusions can be drawn.
Links between inflammation and self-harm reported by existing
observational studies may be due to reverse causality i.e. self-harm
causing inflammation, or confounding, for example by the presence of
chronic and painful diseases that are associated with both suicide risk
and inflammation (Singhal et al., 2014). Indeed, not all studies of the
relationship between IL-6 and suicidal behaviours find associations
(Ganança et al., 2016). Compared with observational studies using
conventional regression methods, MR studies are less likely to be af-
fected by reverse causality and reduce bias due to unmeasured con-
founding.
4.1. Strengths and limitations
The instruments we used for CRP were generated from a large
sample size, and genetic instruments for CRP have been shown to be
strong, reflecting up to 5% of variation in measured CRP levels (Ligthart
et al., 2018). However, instruments for IL-6 are less well established.
Only two existing GWAS studies of IL-6 had been published prior to the
current study (Naitza et al., 2012; Ahola-Olli et al., 2017), one of which
we meta-analysed with our GWAS in the ALSPAC cohort in order to
increase power and sample size. Despite this, our total sample was still
under 10,000. Because of the limited number of instruments for IL-6
and our relatively small sample size (in genetic epidemiology terms),
we had limited power to detect effects of IL-6 in our MR. The samples
for our exposures and outcomes in the current study were restricted to
those of European ancestry, limiting the possibility of population stra-
tification bias, but further reducing sample size. We explored the in-
fluences of two inflammatory markers that have previously been shown
to be associated with self-harm and suicidal behaviour, however in a
biological pathway leading to a complex outcome such as self-harm
many molecules and agents will be implicated, so we are limited in
what can be inferred from examining only two of these markers.
A strength of our study was that we are the first to assess relation-
ships between inflammation and self-harm using genetically-informed
methods. Our GWAS of self-harm overcomes limitations of existing
GWASs of suicidal behaviour as the sample was non-clinical, and most
cases of self-harm do not come to clinical attention (Hawton et al.,
2012). Existing GWASs of suicidal behaviour focus on suicide attempt
ascertained from clinical records, subject to case identification bias as
only around half of individuals who attempt suicide present to services
(McManus et al., 2016), and we have expanded currently limited
knowledge about the genetic architecture of self-harm. However, our
Table 2
Two sample MR and MVMR results.
Two sample MR (total effects) Multivariable MR (direct
effects) n SNPs = 46
Method Biomarker OR 95% CI p OR SE p
IVW IL-6 1.14 (0.90,
1.45)
0.28 1.09 1.10 0.37
CRP 0.92 (0.84,
1.01)
0.08 0.92 1.05 0.09
Egger IL6 1.11 1.12 0.36
CRP 0.86 (0.74,
1.00)
0.05 0.92 1.05 0.09
Notes: IVW: inverse variance weighted; IL-6 Interleukin-6, CRP C-reactive
protein. OR odds ratio 95% CI 95% confidence interval, SE standard error. In
two sample MR the effects of IL-6 on self-harm, and CRP on self-harm, are
estimated in separate models. In multivariable MR IL-6 and CRP are modelled
simultaneously, being conditioned on each other.
Table 3
Two sample MR – suicide attempt.
Interleukin-6 (n SNPs = 2) C-reactive protein (n SNPs = 47)
Model OR 95% CI p OR 95% CI p
IVW 0.83 (0.38,
1.81)
0.64 1.24 (0.81, 1.91) 0.33
MR Egger 1.60 (0.82, 3.14) 0.18
Weighted median 1.31 (0.70, 2.47) 0.40
Simple mode 1.08 (0.32, 3.66) 0.90
Weighted
mode
1.44 (0.83, 2.49) 0.20
Notes: IVW inverse variance weighted, OR odds ratio CI confidence interval,
SNP single nucleotide polymorphism (genetic instrument).
Table 4
Multivariable MR results – suicide attempt.
Two sample MR (total effects) Multivariable MR (direct
effects) n SNPs = 46
Method Biomarker OR 95% CI p OR SE p
IVW IL-6 0.83 (0.38,
1.81)
0.64 0.89 1.23 0.57
CRP 1.24 (0.81,
1.91)
0.32 1.25 1.23 0.28
Egger IL-6 1.04 1.26 0.88
CRP 1.60 (0.82,
3.14)
0.18 1.25 1.22 0.28
Notes: IVW: inverse variance weighted; IL-6 Interleukin-6, CRP C-reactive
protein. OR odds ratio 95% CI 95% confidence interval, SE standard error, SNP
single nucleotide polymorphism (genetic instrument). In two sample MR the
effects of IL-6 on self-harm, and CRP on self-harm, are estimated in separate
models. In multivariable MR IL-6 and CRP are modelled simultaneously, being
conditioned on each other.
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study had limitations regarding the generalisability of our GWAS
findings. Although we had a large sample size of ~150,000 individuals
from UK Biobank, the prevalence of self-harm (4.4%) was lower than
expected given the prevalence of lifetime non-suicidal self-harm of
7.3% and suicide attempt of 6.7% in UK population-representative data
(McManus et al., 2016). Participants in UK Biobank are not re-
presentative of the UK population: they are of higher SES and more
physically and mentally healthy, and both rates and reporting of self-
harm may be biased (Fry et al., 2017). There is a need for further
studies using representative population samples to collect data on self-
harm and other suicidal behaviours in addition to genetic data in order
to increase our understanding of the genetic architecture of these traits
beyond psychiatric populations.
5. Conclusion
This is this first study of which we are aware that investigates po-
tential causal associations between levels of two commonly-measured
inflammatory markers and self-harm, using genetic epidemiological
methods. Our findings are conflicting and indicate that the in-
flammatory markers IL-6 and CRP are not robust aetiological markers of
increased risk of self-harm or suicide attempt. Individual inflammatory
molecules may have differential associations with self-harm, and fur-
ther research should aim to pinpoint hypothesised mechanisms of ac-
tion between inflammatory molecules and risk of self-harm or suicide.
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